Calder, Christopher
Faculty Member
Positions
-
- Affiliation
-
- Publications
-
- Research
-
- Background
-
- Contact
-
- View All
-
Affiliation
Publications
presentations
-
invited talk
-
Alzheimer’s Disease Update,” and “Migraine Headaches,” New York State Academy of Family Physicians & Lake Placid Sports Medicine Society,
Speaker,
Lake Placid, NY
-
Briefing on Health Care Financial Advice Quality Study ,
Speaker,
Healthcare Association of New York State
-
Current Therapies and Standards for Stroke Prevention ,
Speaker,
Teleconference sponsored by IPRO, American Heart Assn. & Healthcare Assn. of NYS
-
Developments In Treatment of Alzheimer’s Disease ,
Speaker,
Alzheimer’s Association, Northeastern New York Chapter
-
Disability and Diabetic Neuropathy,
Speaker,
22nd Annual Education Conference of the Association of Admnistrative Law Judges, Santa Fe, NM
-
Medical Management of Seizure Disorders,
Speaker,
NY State Academy of Family Physicians Winter Wekkend, Lake Placid, NY
-
Migraine Diagnosis & Treatments-Simulated Patients, A New Teaching Tool,
Speaker,
Saratoga Springs, New York
-
Stroke Management,” The Regional Cardiovascular ,
Speaker,
Health Summit Broadway Millennium Hotel, New York, NY
-
“Developments In Treatment of Alzheimer’s Disease,” Alzheimer’s Association ,
Speaker,
Northeastern New York Chapter
-
“Medical Management of Seizure Disorders” Grand Rounds, Albany Memorial Hospital ,
Speaker,
Albany, NY
Research
principal investigator on
-
: PRISM Registry: A Pseudobulbar Affect Registry Series, Avanir Pharmaceuticals
- 2011
-
A Multi-Center, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson’s Disease, Chelsea Therapeutics, Inc.
- 2010
-
A Multi-Center, Open-Label Study to Assess the Long-Term Safety of Droxidopa in Subjects with Primary Autonomic Failure, Dopamine Beta Hydroxylase Deficiency or Non-Diabetic Neuropathy and Symptomatic Neurogenic Orthostatic Hypotension, Chelsea Therapeutics, Inc.
- 2010
-
A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of (S,S)-Reboxetine (PNU-165442G) Administered Once Daily (Q.D.) in Patients with Fibromyalgia.Pfizer.
- 2008
-
A Multi-Center, Long-Term, Open-Label Extension Study of (S,S)-Reboxetine (PNU-165442G) Administered Once Daily in Patients with Fibromyalgia, Pfizer.
- 2008
-
A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Crossover Study to Evaluate the Efficacy of TREXIMET (Sumatriptan + Naproxen Sodium) versus Butalbital-Containing Combination Medications (BCM) for the Acute Treatment of Migraine When Administered During the Moderate-Severe Pain Phase of the Migraine, GlaxoSmithKline.
- 2008
-
A Long-Term, Open-Label Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia, Jazz Pharmaceuticals.
- 2007
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Efficacy and Safety of 100mg/day and 300mg/day Lacosamide for Migraine Prophylaxis, Schwarz Pharma.
- 2007
-
A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (sodium oxybate) in Subjects with Fibromyalgia, Jazz Pharmaceuticals.
- 2007
-
A 12-Week Open-Label Safety Trail of Pregablin in Patients with Fibromyalgia, Pfizer
- 2006
-
Effect of Septal Closure of Atrial PFO on Events of Migraine with Premere: ESCAPE Migraine Trial, Velocimed.
- 2006
-
A Double- Blind, Placebo- Controlled Study of VP4896 for the Treatment of Mild-to-Moderate Alaheimer’s Disease, Voyager Pharmaceuticals.
- 2005
other research activities
-
Phase 3 Randomized, Double-Blind, Pacebo-Controlled Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% Solution (IVIG, 10%) for the Treatment of Mild to Moderate Alzheimer's Disease (AD), Baxter Innovations
Sub-Investigator - 2012
-
A Multinational, Multicenter, Open-Label, Single-Assignment Extension of the MS-LAQ-302 (BRAVO) Study, to Evaluate the Long-term Safety, Tolerability and Effect Disease Course of Daily Oral Laquinimod .6mg in Subjects with Relapsing Multiple Sclerosis, Teva Neuroscience
Sub-Investigator - 2011
-
A Phase2, 24 month, Multi-Center, randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Amyloid-Imaging Positron Emission Tomography (PET) and Safety Study od ACC-001 and QS-21 Adjuvant in Subjects with Mild to moderate Alzeheimer's Disease, Janssen Alzheimer Immunotheraphy
Sub-Investigator - 2011
-
A phase 2, Double-Blind, Randomized, Placebo Controlled, Four-Arm, Multicenter,Dose-Finding Study to Assess the Safety and Efiicacy of Three Dose Levels of AVP- 923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis, Avanir Pharmaceuticals
Sub-Investigator - 2011
-
A randomized Double-Blind Placebo and Active Comparator-Controlled Study of DS-5565 for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy, Daiichi Sankyo Inc.
Sub-Investigator - 2011
-
An Open-Label Pilot Study to Assess Potential Mechanisms for Fybromyalgia in Peripheral Tissue Innervation that Could Predict Theraupeutic Responsiveness to Milnacipran (2737), Forest Research Institute, Inc.
Sub-Investigator - 2011
-
Continued Efficacy and Safety Monitoring of Solanezumab, an Anti-Amyloid B Antobody in Patients with Alzheimer Disease, Eli Eli Lilly and Company
Sub-Investigator - 2011
-
Double-Blind Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Two Doses of Oral Dalfampridine Extended Release Tablets (5mg and 10mg twice daily) in Patients with Multiple Scclerosis, Acorda Theraupeutics Inc.
Sub-Investigator - 2011
-
JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri®: STRATIFY-2, Biogen Idec, Inc.
Sub-Investigator - 2010
-
: A Phase III, Randomized, Double-Blind, Placebo-controlled, Multi-center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS, EMD Serono, Inc
Sub-Investigator - 2009
-
A 2-Year, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II-III Study to Evaluate the Efficacy and Safety of Oral Ranirestat (40 and 80mg) in Mild to Moderate Diabetic Sensorimotor Polyneuropathy, Eisa
Sub-Investigator - 2009
-
A Multicenter Study for the Validation of ALS Biomarkers, Northeast Amyotrophic Lateral Sclerosis Consortium
Sub-Investigator - 2009
-
A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects with Moderately Severe Diabetic Neuropathy, Sangamo Biosciences, Inc
Sub-Investigator - 2009
-
A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s Disease who Participated in Study ELN115727-301 or in Study ELN115727-302, JANSSEN
Sub-Investigator - 2009
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Functions in Patients with a First Episode of Acute Optic Neuritis (AON), Teva Neuroscience
Sub-Investigator - 2009
-
Clinical Trial of Ceftriaxone in Subjects with Amyotrophic Lateral Sclerosis, National Institute of Neurological Disorders and Stroke Sub-Investigator
Sub-Investigator - 2009
-
Effect of LY2062430, an Anti-Amyloid Beta Monoclonal Antibody, on the Progression of Alzheimer’s Disease as Compared with Placebo, Eli Lilly and Company
Sub-Investigator - 2009
-
Immunolabeling Evaluation of Five Selected Markers in Skin Biopsies of Patients with Diabetic Painful Neuropathy (DPN) and Patients with Postherpetic Neuralgia (PHN), and Age and Gender-Matched Normal Controls, Vertex Pharmaceuticals (San Diego), LLC
Sub-Investigator - 2009
-
Long-Term Follow-up of Subjects Exposed to or Treated with SB-509 Plasmid Gene Therapy, Sangamo Biosciences, Inc
Sub-Investigator - 2009
-
Named Patient Program with Rotigotine Transdermal System, Schwarz Biosciences, Inc.
Sub-Investigator - 2009
-
: A Randomized, Multinational, Double-Blind, Placebo-Controlled Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment with Glatiramer Acetate in Subjects with Multiple Sclerosis, Sanofi-Aventis.
Sub-investigator - 2008
-
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients with Amyotrophic Lateral Sclerosis and Multiple Sclerosis, Avanir Pharmaceuticals.
Sub-investigatoe - 2008
-
A Multicenter, Double-Blind, Placebo-Controlled Study of the Effect of SSR180575 at 2 Doses for 24 Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients with Mild Diabetic Peripheral Neuropathy, Sanofi-Aventis.
Sub-investigator - 2008
-
A Multicenter, Open-Label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures, Schwarz Pharma.
Sub-investigator - 2008
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombic Ischemic Events (TRA 2˚P-TIMI 50), Schering-Plough.
Sub-investigator - 2008
-
A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon B-1a (Avonex), in a Rater-Blinded Design, Teva Neuroscience.
Sub-investigator - 2008
-
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Bapineuzumab (AAB-001, ELN115727) in Patients with Mild to Moderate Alzheimer’s Disease Who Are APOE Carriers, Elan.
Sub-investigator - 2008
-
A Pilot, Investigator-Initiated Study of Misfolded Proteins in Neurological Diseases.
Sub- Investigator - 2008
-
A Pilot, Investigator-Initiated Study of the Neurophysiology and Epitope Expression in the Skin of Patients with Neurofibromatosis Type-1.
Sub- Investigator - 2008
-
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Safety and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer’s Disease, Elan.
Sub-investigator - 2008
-
An International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Two Year Treatment with Teriflunomide 7mg Once Daily and 14 mg Once Daily versus Placebo in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis, Sanofi-Aventis.
Sub-investigator - 2008
-
Open-Label Extension Study of 23mg Donepezil SR in Patients with Moderate to Severe Alzheimer’s Disease, Elan.
Sub-investigator - 2008
-
: A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Diabetic Neuropathy, Sangamo Biosciences.
Sub-Investigator - 2007
-
: A Pilot, Investigator- Initiated Study of Sensory Nerve Fiber Count and Epitope Expression in the Skin of Patients with Amyotrophic Lateral Sclerosis (ALS), ALS Regional Center, Saint Peter’s Hospital.
Sub-investigator - 2007
-
: Double-Blind, Parallel-Group Comparison of 23 mg Donepezil Sustained Release to 10 mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer’s Disease, Eisai, Sub-Investigator
Sub-Investigator - 2007
-
A 52 Week Open-Label Extension Study of the Long-Term Safety and Efficacy of Rosiglitazone Extended-Release (RSG XR) as Adjunctive Therapy to Acetylcholinesterase Inhibitors in Subjects with Mild-to-Moderate Alzheimer’s Disease (REFLECT-4), GlaxoSmithKline.
Sub-Investigator - 2007
-
A Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis, BioMS.
Sub-Investigator - 2007
-
A Historical-Controlled, Multicenter, Double-Blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-Onset Seizures, Schwarz Pharma.
Suib-investigator - 2007
-
A Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy, Eisai.
Sub-investigator - 2007
-
A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity, Sangamo Biosciences.
Sub-Investigator - 2007
-
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Design to Evaluate the Efficacy and Safety of Teriflunomide (HMR 1726D) in Reducing the Frequency of Relapses and Delaying the Accumulation of Physical Disability in Subjects with Multiple Sclerosis with Relapses, Sanofi-Aventis.
Sub-Investigator - 2007
-
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis, Biogen.
Sub-Investigator - 2007
-
A Randomized-Withdrawal Phase III Study Evaluating The Safety and Efficacy of CG5503 Extended-Release (ER) in Subjects with Painful Diabetic Neuropathy (DPN) Grunenthal J & J PRD
Sub-investigator - 2007
-
An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled,in Patients with First Clinical Episode Suggestive of Multiple Sclerosis, Sanofi-Aventis. Sub-Investigator
Sub-Investigator - 2007
-
Phase 3 Multicenter, Open Label Study of the Effect of Daily Treatment with MPC-7869 in Subjects with Dementia of the Alzheimer’s Type, Myriad.Sub-investigator
Sub-Investigator - 2007
-
: A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension Phase, Allergan.
Sub-Investigator - 2006
-
: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study Designed to Assess the Efficacy and Safety of FK1706 in a Capsaicin-Induced Denervation Model in Subjects with Diabetic Neuropathy, Astellas.
Sub-Investigator - 2006
-
: [S,S]-Reboxetine Dose-Range Finding Trial: A 16-Week, Randomized, Double-Blind, Placebo and Pregabalin Controlled, Multi-Center Trial of [S,S]-Reboxetine in Patients with Postherpectic Neuralgia (PHN), Pfizer.
Sub-Investigator - 2006
-
A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared with Ropinirole Immediate Release (IR) Tablets in Subjects with Restless Legs Syndrome (RLS), GlaxoSmithKline.
Sub-Investigator - 2006
-
A Long-Term Study of XP13512 versus Placebo Treatment Assessing Maintenance of Efficacy and Safety in Patients with Restless Legs Syndrome, Xenoport.
Sub-Investigator - 2006
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients with Pain Associated with Diabetic Peripheral Neuropathy, Wyeth.
Sub-Investigator - 2006
-
A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20 mg, 40 mg and 80 mg of MCC-257 in Patients with Mild to Moderate Diabetic Polyneuropathy, Mitsubishi.
Sub-Investigator - 2006
-
An Open-Label Extension Study Evaluating the Safety and Tolerability of Memantine in Patients with Moderate to Severe Dementia of the Alzheimer’s Type, Forest Research Institute.
Sub-Investigator - 2006
-
An Open-Label Extension Trial to Investigate the Safety and Tolerability of Long-Term Treatment with Transdermal Rotigotine in Subjects with Idiopathic Restless Legs Syndrome, Schwarz Pharma.
Sub-Investigator - 2006
-
Carotid Angioplasty and Stenting versus Endarterectomy in Asymptomatic Subjects with Significant Extracranial Carotid Occlusive Disease, Abbott Labs.
Sub-Investigator - 2006
-
Emboshield and Xact Post Approval Carotid Stent Trial Using the Emboshield Bare Wire Rapid Exchange Embolic and Xact Rapid Exchange Carotid Stent System, Abbott Labs.
Sub-Investigator - 2006
-
: A Double-Blind, Phase II, Safety and Efficacy Evaluation of ONO-2506PO in Patients with Mild to Moderate Alzheimer's Disease, Ono Pharmaceuticals.
Sub-Investigator - 2005
-
: Dose Response Study of Duloxetine versus Placebo in the Treatment of Fibromyalgia Syndrome, Eli Lilly and Company.
Sub-Investigator - 2005
-
A 14-Week, Randomized, Double-Blind, Placebo-Controlled Trial of Pregabalin Twice Daily in Patients with Fibromyalgia, Pfizer.
Sub-Investigator - 2005
-
A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dextromethorphan and Quinidine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy, Avanir Pharmaceuticals.
Sub-Investigator - 2005
-
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects with Idiopathic Restless Legs Syndrome, Schwarz Pharma.
Sub-Investigator - 2005
-
A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients with Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN), NeurogesX.
Sub-Investigator - 2005
-
A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Saftety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment, Eisai, Inc.
Sub-Investigator - 2005
-
A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Memantine in Patients with Moderate-to-Severe Dementia of the Alzheimer's Type, Forest Research Institute.
Sub-Investigator - 2005
-
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2 Study Designed to Assess the Efficacy and Safety of FK1706 in Subjects with Painful Diabetic Neuropathy, Astellas Pharma US.
Sub-Investigator - 2005
Background
education and training
credential eligibility attained
